药物性肝损伤的生物标志物及其评价的研究进展  

Progress in biomarkers and evaluation of drug-induced liver injury

作　　者：高绪聪[1] 柴振海[1] 张宗鹏[1] 

机构地区：[1]天津药物研究院新药安全评价研究中心,天津300193

出　　处：《中国药理学与毒理学杂志》2012年第5期692-696,共5页Chinese Journal of Pharmacology and Toxicology

基　　金：国家科技重大专项基金(2012ZX09505001-001)~~

摘　　要：药物性肝损伤是伴随药物使用而出现的主要不良反应,是肝疾病的主要组成部分,目前血清天冬氨酸转氨酶、丙氨酸转氨酶、碱性磷酸酶和总胆红素等传统标志物在药物性肝损伤的预测和诊断中的地位尚无可取代,但近年发现的血清药物-蛋白加合物、嗜酸性粒细胞、乳酸脱氢酶、谷氨酰胺脱氢酶及基因组学生物标志物等多种新的生物标志物对弥补传统生物标志物检测敏感性和特异性的作用也不可忽视。本文结合药物性肝损伤评价现状对传统生物标志物和近年发现的新的肝损伤生物标志物进行概述,为更好地预测和诊断肝损伤、减轻药物性危害提供可能的帮助。Drug-induced liver injury（DILI） is the main serious reaction during drug use and the major component of liver disease.Traditional biomarkers,such as alanine transaminase,aspartate aminotransferase,alkaline phosphatase,total bilirubin,have been irreplaceable in drug-induced liver injury prediction and diagnosis,but in recent years some new biomarkers,such as serum drug-protein adducts,eosinophils,lactate dehydrogenase,glutamine dehydrogenase and genomic biomarkers,have been found to be able to make up for the detection sensitivity and specificity of traditional biological markers.This paper summarizes the traditional biomarkers and newly discovered liver injury biomarkers combined with DILI evaluation in order to better forecast and diagnose liver damage while reducing drug harm.

关 键 词：肝损伤 药物毒性 药物评价 

分 类 号：R595.3[医药卫生—内科学]